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Abstract
Background: There are few data on the joint influence of metabolic factors on risk of sep-
arate cancers.
Methods: We analysed data on body mass index, blood pressure and plasma levels of
glucose, total cholesterol and triglycerides from seven European cohorts comprising
564 596 men and women with a mean age of 44 years. We weighted those factors equally
into a standardized metabolic risk score [MRS, mean¼0, standard deviation (SD)¼ 1],
with an individual’s level indicated as SDs from the sex- and cohort-specific means.
Cancer hazard ratios were calculated by Cox regression with age as timescale and with
relevant adjustments including smoking status. All statistical tests were two-sided.
Results: During a mean follow-up of 12 years, 21 593 men and 14 348 women were diag-
nosed with cancer. MRS was linearly and positively associated with incident cancer in
total and at sites (P< 0.05). In men, risk per SD MRS was increased by 43% (95% confi-
dence interval: 27–61) for renal cell cancer, 43% (16–76) for liver cancer, 29% (20–38) for
colon cancer, 27% (5–54) for oesophageal cancer, 20% (9–31) for rectal cancer, 19%
(4–37) for leukaemias, 15% (1–30) for oral cancer and 10% (2–19) for bladder cancer. In
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women, risk increases per SD MRS were 56% (42–70) for endometrial cancer, 53%
(29–81) for pancreatic cancer, 40% (16–67) for renal cell cancer, 27% (9–47) for cervical
cancer and 17% (3–32) for rectal cancer.
Conclusion: This largest study to date on the joint influence of metabolic factors on risk
of separate cancers showed increased risks for several cancers, in particular renal cell
and liver cancer in men and endometrial and pancreatic cancer in women.
Key words: cohort studies, metabolic syndrome x, neoplasms
Introduction
There is substantial evidence that obesity increases the risk of
many cancers.1 The risk is particularly increased for oesopha-
geal adenocarcinoma, renal cell carcinoma, colorectal cancer,
endometrial cancer and postmenopausal breast cancer.1–6
Much less is known about the association between other
metabolic aberrations and the risk of cancer. However, recent
years have shown an increased interest in a putative associ-
ation between cancer and the metabolic syndrome: a constel-
lation of obesity and insulin resistance, hypertension and
dyslipidaemia.7 Studies of common cancers have shown that
individuals with the metabolic syndrome have an increased
risk of cancer of the colorectum, pancreas and endomet-
rium.5,6,8,9 However, the analytical approach to the meta-
bolic syndrome has been very heterogeneous between
studies,8 so the strength of associations with various cancers
remains unclear and data on rare cancers are lacking.
To date, most studies of the metabolic syndrome have
dichotomized ingoing factors into low-risk and high-risk
groups, which finds little support in the literature for car-
diovascular disease.10 Also, in our analyses of more than
500 000 individuals, we found linear associations between
cancer risk and both blood glucose11 and blood pressure,12
which is unsupportive to the use of dichotomization. By
use of a continuous metabolic risk score (MRS) comprising
equal weights from body mass index (BMI), blood pressure
and plasma levels of glucose, triglycerides and total choles-
terol, we have assessed the risks of several separate cancers
(see e.g. references 3, 5, 6, 9, 13, 14, 19, 28, 29 and 30).
In this study, we report the association between MRS
and the risk of cancer overall and at separate sites. We as-
sess the strength and shape of association between MRS
and total cancer incidence and cancer mortality, and with
a large number of separate cancers for a direct comparison
of their strength of associations with the MRS.
Methods
The Me-Can cohort
The Me-Can project pools data from seven cohorts in
Norway, Sweden and Austria. A detailed description and
the inclusion criteria for the 578 700 participants are re-
ported elsewhere.13 In brief, cohort health examinations
performed between 1975 and 2005 (see Table 1) include
measurements of height, weight, blood pressure and circu-
lating levels of glucose, total cholesterol and triglycerides.
In the present study with MRS as the primary exposure,
we excluded 14 104 (2%) individuals because of incom-
plete data for one or more variable in the MRS, leaving
564 596 participants (281 193 men and 283 403 women)
in the study. The study was approved by research ethical
committees in Norway, Austria and Sweden.
Follow-up
The cohorts were linked to their respective national register
for identification of cancer incidence, migration (except for
the Austrian cohort, for whom there was no information),
Key Messages
• In this pooled study of seven European cohorts, high levels of a metabolic risk score of five components—BMI, blood
pressure and plasma levels of glucose, total cholesterol and triglycerides—were related to increased overall risks of
cancer incidence and mortality in men and in women.
• The highest risk increases were found for renal cell and liver cancer in men, and for endometrial and pancreatic can-
cer in women.
• The strongest individual risk factors for total incident cancer were in men high levels of blood pressure and triglycer-
ides, and in women high plasma glucose.
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Table 1. Baseline characteristics of study participants in the Metabolic Syndrome and Cancer project (Me-Can)
Characteristics Men Women
Cohort (year of baseline measurement), n (%)
Oslo (1972–73) 16 760 (6)
NCS (1974–83) 25 952 (9) 25 072 (9)
CONOR (1995–2003) 52 181 (18) 57 687 (20)
40-y (1994–99) 60 676 (22) 68 211 (24)
VHM&PP (1988–2002) 72 858 (26) 86 132 (30)
VIP (1986–2005) 30 699 (11) 35 871 (13)
MPP (1974–92) 22 067 (8) 10 430 (4)
Total (1972–2005) 281 193 283 403
Baseline age, years
Mean (SD) 43.9 (11.1) 44.1 (12.3)
Categories, n (%)
<30 26 744 (9) 32 751 (11)
30–44 153 479 (55) 152 321 (54)
45–59 73 219 (26) 65 464 (23)
60 27 751 (10) 32 867 (12)
Fasting time, h, n (%)a
<4 119 927 (43) 121 874 (43)
4–7 29 468 (10) 25 760 (9)
8 131 798 (47) 135 769 (48)
Smoking status, n (%)
Never smoker 108 662 (39) 141 502 (50)
Ex-smoker 84 154 (30) 71 759 (25)
Current smoker 87 778 (31) 69 628 (25)
Not known 599 (0) 514 (0)
BMI, kg/m2
Mean (SD) 25.7 (3.5) 24.9 (4.4)
Category,b n (%)
<25 127 066 (45) 167 173 (59)
25–29.9 124 030 (44) 81 341 (29)
30 30 097 (11) 34 889 (12)
Blood pressure, mmHg
Mean (SD) systolic blood pressure 132.8 (16.9) 126.9 (19.4)
Mean (SD) diastolic blood pressure 81.3 (11.0) 76.8 (11.3)
Mean (SD) mid blood pressurec 107.0 (12.7) 101.8 (14.2)
Category,b systolic/diastolic, n (%)
<140/90 173 824 (62) 209 385 (74)
140/90–159/99 77 382 (27) 49 792 (18)
160/100 29 987 (11) 24 226 (8)
Glucose, mmol/l
Mean (SD)d 5.1 (1.3) 5.0 (1.2)
Category,b n (%)e
<6.1 in serum/plasma or <5.6 in whole blood 115 966 (88) 123 643 (91)
6.1–6.9 in serum/plasma or 5.6–6.0 in whole blood 10 719 (8) 8233 (6)
7.0 in serum/plasma or 6.1 in whole blood 5113 (4) 3893 (3)
Cholesterol, mmol/l
Mean (SD) 5.6 (1.2) 5.6 (1.2)
Category,b n (%)e
<5.2 48 768 (37) 56 050 (41)
5.2–6.1 44 165 (34) 43 418 (32)
6.2 38 865 (29) 36 301 (27)
Triglycerides, mmol/l
Mean (SD) 1.6 (1.2) 1.3 (0.8)
(Continued)
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vital status and cause of death. Follow-up for cancer inci-
dence/mortality included the year 2005/04 in Norway,
2006/04 in Sweden and 2003/03 in Austria. We categorized
incident cancers according to the International
Classification of Diseases, 7th revision (ICD-7). ICD-7 was
used during the first years of follow-up for the older cohorts
so, for consistency, we used it for all cohorts.
Statistical analysis
We investigated the associations of cancer incidence and
mortality with BMI, blood pressure and blood levels of
glucose, total cholesterol and triglycerides by quintiles, and
with MRS by quintiles and as a continuous Z-distributed
variable. We constructed the MRS based on these five com-
ponents, which we first converted to a Z-distribution by
(level, mean)/SD within the corresponding cohort and sex,
and also within categories of fasting time for measures of
glucose, cholesterol and triglycerides. We used mid blood
pressure [(systolic blood pressure þ diastolic blood pres-
sure)/2],15 and we log-transformed glucose and triglyceride
levels before standardization because their distributions
were skewed. We standardized the sum of Z-scores of sin-
gle factors within each cohort, sex and fasting time. This
resulted in an MRS with a mean value of zero and an SD
of one, with equal weight from each factor. Quintile cut-
points were calculated separately within each cohort and
sex, and also within categories of fasting time for measures
of glucose, cholesterol and triglycerides.
We used Cox proportional hazards regression to calcu-
late cancer hazard ratios (HRs) for MRS and its ingoing
factors. To reduce the probability of reverse causation,
follow-up started at 1 year after the baseline examination
and ended at the date of the event—i.e. the date of the first
cancer diagnosis or cancer death or of death from any
cause or of emigration or until end of follow-up, whichever
occurred first. We used age as time variable and stratified
all models by cohort and by birth year category (before
1923, 1923–30, 1931–38, 1939–46, 1947–54, 1955 and
later), and analyses of men and women combined were
also stratified by sex. We adjusted all analyses for age at
measurement (continuous), smoking status (never smoker,
ex-smoker, current smoker, unknown), and quintile ana-
lysis for BMI (quintiles). We performed separate analyses
for men and women when the number of cases for either
sex was at least 50. We tested for potential differences be-
tween the sexes and cohorts, respectively, regarding HRs
of cancer by the MRS and its components. We used likeli-
hood ratio tests in which a model with the continuous
MRS, or quintiles of MRS components, was compared
with a model additionally including a product term of
these exposures and sex or cohort.
To investigate the shape of the association between MRS
and cancer risk we used restricted cubic spline regression16
with knots placed at percentiles 5, 35, 65 and 95. We also per-
formed a formal test for linearity of the association by compar-
ing the fit of the linear model with the fit of the cubic spline
model using likelihood-ratio tests in which the linear model
was nested in a model that additionally included cubic splines.
We adjusted HRs for random error in the measurement
of exposure factors by dividing the regression coefficient in
the Cox model by the estimated regression dilution ratio
(RDR) of exposure,17 as previously described in detail.5
We based these calculations on data from 133 820
Table 1. Continued
Characteristics Men Women
Category,b n (%)e
<1.7 89 262 (68) 112 183 (83)
1.7–2.2 20 481 (15) 14 072 (10)
2.3 22 055 (17) 9514 (7)
Follow-up, years
Mean (SD) 12.8 (8.7) 11.2 (6.9)
Category, n (%)
<5 36 488 (13) 35 325 (12)
5–14 172 479 (61) 196 029 (69)
15–24 23 158 (8) 27 586 (10)
25 49 068 (18) 24 463 (9)
Oslo, Oslo study I; NCS, Norwegian Counties Study; CONOR, Cohort of Norway; 40-y, Age 40-Programme; VHM&PP, Vorarlberg Heath Monitoring and
Prevention Programme; VIP, Va¨sterbotten Intervention Project; MPP, Malmo¨ Preventive Project; SD, standard deviation; BMI, body mass index.
aProportion of participants with fasting time 8 h: 5% in the Norwegian cohorts, 92% in the VIP and 100% in the VHM&PP and MPP.
bSource for categories: BMI20, blood pressure21, glucose22, cholesterol and triglycerides23.
c(Systolicþ diastolic blood pressure)/2.
dIncludes 109 731 men and 125 339 women with fasting plasma or serum samples. Participants in MPP, with glucose measured in whole blood, are not
included.
eIncludes 131 798 men and 135 769 women with fasting plasma/serum/blood samples.
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participants for whom two or more observations with the
same fasting time before measurements were available,
406 364 observations in total. We based RDR calculations
on linear mixed effect models17,18 and obtained RDR val-
ues of 0.90 for BMI, 0.53 for systolic blood pressure, 0.50
for diastolic blood pressure, 0.28 for log(glucose), 0.66 for
cholesterol, 0.51 for log(triglycerides) and 0.69 for MRS.
We corrected all HRs for random error using the equation
HRcorrected¼ exp(log(HR)/RDR).
Proportional hazards assumptions of the Cox model for
total cancer incidence and cancer mortality were tested by
Schoenfeld residuals statistics, and proportionality of MRS
was additionally evaluated by inclusion of MRS as a time-
dependent variable in the model. There were indications of
violation for smoking status in relation to incident cancer
in women, but inclusion of smoking status as stratum in
the Cox model did not affect HRs, so it was not retained in
the model. Proportionality was also indicated to be vio-
lated for MRS and incident cancer in women. This obser-
vation was largely driven by breast cancer for which we
have previously reported results in detail for MRS and its
components in relation to breast cancer risk in groups of
attained age.19 In analyses of total incident cancer in
women, proportional hazards were no longer violated after
exclusion of breast cancers.
We performed statistical analyses in Stata (version 10.0)
and R (version 2.7.2 for RDR calculations). All statistical
tests were two-sided.
Results
Table 1 shows the characteristics of the study participants
at baseline. Mean age was 44.0 years (SD¼ 11.7); 44% of
men and 29% of women were overweight (BMI
25–29.9 kg/m2), and 11% of men and 12% of women
were obese (BMI30 kg/m2). Mean follow-up time was
12.8 years (SD¼ 8.7) among men and 11.2 years
(SD¼ 6.9) among women. Calculations of HRs for cancer
included 3 230 484 person-years and 21 593 incident can-
cers in men and 2 828 417 person-years and 14 348 inci-
dent cancers in women. The corresponding numbers for
cancer mortality were 3 041 384 person-years and 8572
cancer deaths in men, and 2 653 234 person-years and
4405 cancer deaths in women. Mean levels of metabolic
risk factors, and number of incident cases in each cohort,
are shown in SupplementaryTable 1, available as
Supplementary data at IJE online).
In men, the risk for any cancer for top vs bottom
quintile of metabolic factors was increased by 28% [95%
confidence interval (CI): 17–41%] for diastolic blood pres-
sure (Ptrend<0.001), 23% for systolic blood pressure
(95% CI: 12–33%, Ptrend< 0.001), 20% for triglycerides
(95% CI: 10–32%, Ptrend¼ 0.01) and 17% for MRS (95%
CI: 9–25%, Ptrend< 0.001) (Table 2). These factors and
glucose levels were also related to increased cancer mortal-
ity in men. BMI and cholesterol were related to neither
cancer incidence nor cancer mortality. There were no inter-
actions between metabolic factors in quintiles and cohort
in relation to cancer incidence or mortality in men (Phet all
0.05), except for systolic blood pressure and cancer mor-
tality (Phet¼ 0.02), for which HRs in the top quintile
ranged between 0.37 (95% CI: 0.14–0.94, Ptrend¼ 0.07) in
the Age 40-Programme to 1.96 (95% CI: 1.32–2.90,
Ptrend<0.001) in the Vorarlberg Health Monitoring and
Prevention Programme.
In women, there was a 46% increased risk for any can-
cer for the top vs bottom quintiles of blood glucose (95%
CI: 21–76%, Ptrend< 0.001), 18% for triglycerides (95%
CI: 6–32%, Ptrend¼ 0.001), 12% for BMI (95% CI:
5–19%, Ptrend< 0.001) and 26% for MRS (95% CI:
15–38%, Ptrend< 0.001) (Table 3). A positive trend was
also shown for systolic blood pressure (Ptrend¼ 0.04). The
top cholesterol quintile was related to an 11% decreased
risk of incident cancer in women (95% CI: 2–18%,
Ptrend¼0.01). Top quintiles of systolic and diastolic blood
pressure were not related to incident cancer risk in women.
All factors except cholesterol showed a positive trend for
cancer mortality in women. There were no interactions be-
tween metabolic factors and cohort, except for glucose and
incident cancer (Phet¼ 0.03) that showed HRs for the top
quintile ranging from 0.83 (95% CI: 0.49–1.42,
Ptrend¼0.6) in the Age 40-Programme to 2.11 (95% CI:
1.21–3.67, Ptrend¼0.002) in the Va¨sterbotten Intervention
Project. HRs for quintile analyses differed between men
and women for BMI and glucose in relation to cancer inci-
dence (Pinteraction¼ 0.03 and 0.001) and for glucose, trigly-
cerides and MRS in relation to cancer mortality
(Pinteraction¼ 0.02, 0.046 and 0.01). In both men and
women, results from quintile analyses of MRS, blood pres-
sure, glucose and triglycerides showed stronger associ-
ations with cancer mortality than with cancer incidence,
though confidence intervals were overlapping. Exclusion
of the first 5 years of follow-up did not affect HRs in quin-
tiles for cancer incidence or mortality in men or in women.
In spline models, the MRS was linearly and positively
associated with incident cancer in both men and women
(Figure 1). HRs per SD increment in MRS were 1.05 (95%
CI: 1.03–1.08) in men and 1.08 (95% CI: 1.05–1.11) in
women. The association was also linear and positive for
cancer mortality in women, whereas in men the association
was non-linear with no association observed for levels
below the mean MRS level, but an increased risk for
increasing MRS levels above the mean MRS level (Z¼ 0).
The associations between continuous MRS and cancer
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incidence and mortality did not differ between Me-Can
subcohorts in men or in women (Phet all 0.05).
Associations between continuous MRS and risk of can-
cer at separate sites are shown in Figure 2. A positive
association was found in both sexes for renal cell, colon
and rectal cancer, and several other cancers showed associ-
ations in men or in women. In men, the risk increase per
SD MRS increment was 43% (95% CI: 16–76%) for renal
Table 2. Hazard ratioa of cancer incidence and mortality in men by quintile of metabolic factors
Exposure Quintile Mean (SD) Hazard ratio (95% CI)
Cancer incidence n cases¼21 593 Cancer mortality n cases¼8572
BMI, kg/m2 1 21.5 (1.3) 1.00 (referent) 1.00 (referent)
2 23.8 (0.8) 1.00 (0.95–1.05) 0.89 (0.83–0.96)
3 25.4 (0.8) 0.99 (0.94–1.04) 0.88 (0.82–0.95)
4 27.1 (0.9) 0.99 (0.94–1.04) 0.88 (0.81–0.94)
5 30.8 (2.7) 1.04 (0.99–1.09) 1.02 (0.95–1.10)
Ptrend
b¼0.1 Ptrendb¼0.3
Systolic blood pressure, mmHg 1 112.3 (6.4) 1.00 (referent) 1.00 (referent)
2 122.9 (3.9) 1.02 (0.93–1.11) 1.04 (0.90–1.21)
3 129.8 (4.4) 1.10 (1.01–1.20) 1.22 (1.06–1.40)
4 138.2 (4.4) 1.18 (1.08–1.29) 1.23 (1.07–1.42)
5 156.5 (13.5) 1.23 (1.12–1.33) 1.51 (1.31–1.72)
Ptrend
b<0.001 Ptrend
b<0.001
Diastolic blood pressure, mmHg 1 67.0 (5.0) 1.00 (referent) 1.00 (referent)
2 75.2 (3.2) 1.06 (0.96–1.17) 0.98 (0.84–1.14)
3 80.2 (2.7) 1.09 (0.99–1.19) 1.08 (0.94–1.25)
4 86.3 (3.5) 1.14 (1.04–1.25) 1.15 (0.99–1.33)
5 97.1 (7.7) 1.28 (1.17–1.41) 1.35 (1.16–1.57)
Ptrend
b<0.001 Ptrend
b<0.001
Glucose, mmol/l 1 4.2 (0.5) 1.00 (referent) 1.00 (referent)
2 4.8 (0.3) 1.06 (0.90–1.24) 0.90 (0.70–1.16)
3 5.1 (0.4) 1.10 (0.93–1.29) 1.07 (0.83–1.38)
4 5.5 (0.4) 1.12 (0.96–1.30) 1.06 (0.83–1.36)
5 6.9 (2.0) 1.11 (0.95–1.30) 1.47 (1.16–1.88)
Ptrend
b¼0.2 Ptrendb<0.001
Cholesterol, mmol/l 1 4.3 (0.5) 1.00 (referent) 1.00 (referent)
2 5.1 (0.3) 0.95 (0.89–1.02) 0.96 (0.86–1.07)
3 5.7 (0.3) 0.98 (0.91–1.05) 0.92 (0.82–1.02)
4 6.3 (0.3) 0.96 (0.90–1.03) 0.89 (0.80–1.00)
5 7.4 (0.8) 0.98 (0.91–1.05) 0.97 (0.87–1.09)
Ptrend
b¼0.8 Ptrendb¼0.9
Triglycerides, mmol/l 1 0.8 (0.2) 1.00 (referent) 1.00 (referent)
2 1.2 (0.2) 1.16 (1.07–1.27) 1.05 (0.92–1.21)
3 1.5 (0.3) 1.13 (1.04–1.24) 1.11 (0.96–1.27)
4 2.1 (0.4) 1.18 (1.08–1.28) 1.14 (0.99–1.32)
5 3.7 (1.7) 1.20 (1.10–1.32) 1.33 (1.15–1.53)
Ptrend
b¼0.01 Ptrendb<0.001
Metabolic risk score 1 1.3 (0.4) 1.00 (referent) 1.00 (referent)
2 0.6 (0.2) 1.08 (1.01–1.16) 1.02 (0.92–1.14)
3 0.1 (0.1) 1.11 (1.04–1.18) 1.07 (0.96–1.19)
4 0.5 (0.2) 1.10 (1.03–1.17) 1.09 (0.98–1.21)
5 1.5 (0.6) 1.17 (1.09–1.25) 1.27 (1.14–1.41)
Ptrend
b<0.001 Ptrend
b<0.001
CI, confidence interval; SD, standard deviation; BMI, body mass index.
aHazard ratio from Cox regression model, with attained age as timescale, stratified by cohort and birth year and adjusted for baseline age, smoking status and
quintiles of BMI (except BMI and metabolic risk score). HRs are corrected for regression dilution ratio (RDR); conversion into uncorrected
HR¼ exp(log(HRcorrected)*RDR). RDR: BMI, 0.90; systolic blood pressure, 0.53; diastolic blood pressure, 0.50; log(glucose), 0.28; cholesterol, 0.66; log(trigly-
cerides), 0.51; metabolic risk score, 0.69.
bP-value for the Wald test of a linear risk estimate, assigning each participant the mean cohort-specific level within the corresponding quintile.
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cancer, 43% (95% CI: 27–61%) for liver cancer, 29%
(95% CI: 20–38%) for colon cancer, 27% (95% CI:
5–54%) for oesophageal cancer [58%, (95% CI:
17–114%) for oesophageal adenocarcinoma], 20% (95%
CI: 9–31%) for rectal cancer, 19% (95% CI: 4–37%) for
leukaemias, 15% (95% CI: 1–30%) for oral cancers and
10% (95% CI: 2–19%) for bladder cancer. In women, the
risk increase per SD MRS was 56% (95% CI: 42–70%) for
Table 3. Hazard ratioa of cancer incidence and mortality in women by quintile of metabolic factors
Exposure Quintile Mean (SD) Hazard ratio (95% CI)
Cancer incidence n cases¼14 348 Cancer mortality n cases¼4405
BMI, kg/m2 1 20.0 (1.2) 1.00 (referent) 1.00 (referent)
2 22.2 (0.8) 1.01 (0.95–1.08) 0.85 (0.76–0.96)
3 24.1 (0.8) 1.00 (0.94–1.06) 0.92 (0.82–1.03)
4 26.4 (1.0) 0.99 (0.93–1.05) 0.83 (0.74–0.93)
5 31.7 (3.6) 1.12 (1.05–1.19) 1.04 (0.93–1.16)
Ptrend
b<0.001 Ptrend
b¼0.03
Systolic blood pressure, mmHg 1 104.0 (5.7) 1.00 (referent) 1.00 (referent)
2 114.2 (3.3) 1.01 (0.89–1.13) 1.00 (0.80–1.26)
3 122.5 (3.0) 1.04 (0.92–1.17) 1.04 (0.83–1.31)
4 133.1 (4.9) 0.99 (0.88–1.11) 1.18 (0.95–1.47)
5 156.7 (16.2) 1.10 (0.98–1.24) 1.25 (1.00–1.55)
Ptrend
b¼0.04 Ptrendb¼0.02
Diastolic blood pressure, mmHg 1 61.3 (4.8) 1.00 (referent) 1.00 (referent)
2 70.1 (3.1) 1.00 (0.88–1.13) 1.33 (1.05–1.69)
3 76.8 (3.6) 0.96 (0.86–1.09) 1.23 (0.97–1.55)
4 82.4 (4.7) 1.01 (0.90–1.14) 1.40 (1.11–1.75)
5 92.4 (8.4) 1.08 (0.96–1.22) 1.61 (1.28–2.03)
Ptrend
b¼0.08 Ptrendb<0.001
Glucose, mmol/l 1 4.1 (0.5) 1.00 (referent) 1.00 (referent)
2 4.6 (0.3) 1.01 (0.82–1.24) 1.07 (0.73–1.58)
3 5.0 (0.3) 1.03 (0.85–1.25) 1.24 (0.86–1.78)
4 5.3 (0.3) 1.39 (1.14–1.69) 1.81 (1.26–2.60)
5 6.5 (1.6) 1.46 (1.21–1.76) 2.19 (1.55–3.08)
Ptrend
b<0.001 Ptrend
b<0.001
Cholesterol, mmol/l 1 4.2 (0.4) 1.00 (referent) 1.00 (referent)
2 4.9 (0.2) 0.96 (0.88–1.05) 0.98 (0.82–1.16)
3 5.5 (0.3) 0.94 (0.86–1.02) 0.87 (0.73–1.03)
4 6.1 (0.3) 0.96 (0.88–1.05) 0.99 (0.84–1.16)
5 7.3 (0.9) 0.89 (0.82–0.98) 0.95 (0.81–1.11)
Ptrend
b¼0.01 Ptrendb¼0.7
Triglycerides, mmol/l 1 0.6 (0.1) 1.00 (referent) 1.00 (referent)
2 0.9 (0.1) 1.05 (0.94–1.18) 1.16 (0.93–1.46)
3 1.1 (0.1) 1.01 (0.91–1.13) 1.23 (0.99–1.52)
4 1.5 (0.2) 1.09 (0.98–1.22) 1.44 (1.16–1.78)
5 2.5 (1.1) 1.18 (1.06–1.32) 1.72 (1.39–2.12)
Ptrend
b¼0.001 Ptrendb<0.001
Metabolic risk score 1 1.2 (0.3) 1.00 (referent) 1.00 (referent)
2 0.6 (0.1) 1.15 (1.05–1.25) 1.21 (1.01–1.45)
3 0.1 (0.1) 1.11 (1.01–1.21) 1.24 (1.04–1.48)
4 0.4 (0.2) 1.12 (1.03–1.23) 1.36 (1.14–1.61)
5 1.5 (0.6) 1.26 (1.15–1.38) 1.63 (1.37–1.93)
Ptrend
b<0.001 Ptrend
b<0.001
CI, confidence interval; SD, standard deviation; BMI, body mass index.
aHazard ratio from Cox regression model, with attained age as timescale, stratified by cohort and birth year and adjusted for baseline age, smoking status and
quintiles of BMI (except BMI and metabolic risk score). HRs are corrected for regression dilution ratio (RDR); conversion into uncorrected
HR¼ exp(log(HRcorrected)*RDR). RDR: BMI, 0.90; systolic blood pressure, 0.53; diastolic blood pressure, 0.50; log(glucose), 0.28; cholesterol, 0.66; log(trigly-
cerides), 0.51; metabolic risk score, 0.69.
bP-value for the Wald test of a linear risk estimate, assigning each participant the mean cohort-specific level within the corresponding quintile.
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endometrial cancer, 53% (95% CI: 29–81%) for pancre-
atic cancer, 40% (95% CI: 16–67%) for renal cell cancer,
27% (95% CI: 9–47%) for cervical cancer and 17% (95%
CI: 3–32%) for rectal cancer. One SD increment of the
MRS was also associated with a small [5%, (95% CI:
1–9%)] decrease in breast cancer risk. This association was
driven by results in women who were <50 years old (pre-
menopausal) at the time of diagnosis [18% decreased risk
(95% CI: 10%–25%)], and there was no association in
women 60 years old (postmenopausal) at diagnosis [4%
increased risk (95% CI: –3–12%)].The association be-
tween MRS and gallbladder cancer was non-significant in
men and women separately but was associated with a 28%
(95% CI: 3–60%) risk increment per SD of the MRS in
men and women combined. There were no signifi-
cant interactions between MRS and cohort in relation to
risk of separate cancer forms except for pancreas and
stomach cancer among men (Phet¼ 0.01 and 0.048, re-
spectively) and non-Hodgkin lymphoma among women
(Phet¼ 0.01).
Discussion
In this pooled analysis of seven European cohorts, an MRS
based on equal weights from levels of BMI, blood pressure,
blood glucose, triglycerides and total cholesterol was lin-
early, positively associated with risk of incident cancer in
men and in women. In men, the strongest associations
were found for renal cell cancer and liver cancer, and in
women, associations were the strongest for endometrial
cancer and pancreas cancer. Positive associations were
found for several other cancers.
There is no consensus on the optimal definition of the
metabolic syndrome but all established definitions are based
on a dichotomization of the syndrome and of each compo-
nent variable.7 The relevance of such dichotomization has
been questioned in the field of cardiovascular disease,10,24
and it has not been shown relevant to cancer risk. We there-
fore used a continuous MRS based on equal weights from
five factors in or related to the metabolic syndrome, with an
individual’s level expressed as SDs from the sex- and cohort-
specific mean. Our previous studies have generally shown
Figure 1. Hazard ratio (HR, black line) and 95% confidence interval (shaded area) of cancer incidence (A) (n cases¼ 21 593) and cancer mortality (B) (n
cases¼ 8572) in men, and cancer incidence (C) (n cases¼ 14 348) and cancer mortality (D) (n cases¼ 4405) in women, by the metabolic risk score
(mean¼0, SD¼ 1). Models were derived from restricted cubic spline regression, with knots placed at percentiles 5, 35, 65 and 95. Attained age was
used as timescale, and models were stratified by cohort and birth year and adjusted for baseline age and smoking status. HRs were corrected for a re-
gression dilution ratio of 0.69 for metabolic risk score by exp(log(HR)/0.69). Participants with values more extreme than6 3 SD were excluded from
the analyses (n excluded 1845). P-value LR test, linear-spline, refers to likelihood-ratio tests of the linear model nested in a model with addition of
splines.
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linear associations of single metabolic risk factors with risk
of incident overall cancer,11,12,25,26 and the present analysis
showed the same for MRS, which further supports the use
of linear models in analysis of incident cancer. The linear
model approach also maximizes statistical power, resulting
in robust results for a comparison of effect sizes for the im-
pact of a composite MRS on different cancer forms. The
drawback of our method is that the results are cohort-
specific and cannot be applied to absolute levels and are
therefore not attractive to use in clinical work.
Our results are in accordance with other, mostly smaller
studies, which have shown an increased risk for cancer of
the colorectum, liver, pancreas or endometrium in individ-
uals with the metabolic syndrome.8,27 Strong positive asso-
ciations, as previously reported in Me-Can3,28–30 but in
few other studies, were also shown for MRS and cancer of
the renal cells and gallbladder in both men and women, oe-
sophageal cancer in men and cervical cancer in women.
We also report novel findings for a strong positive associ-
ation between MRS and risk for cancer of the oral cavity
in both men and women. For total cancer in both men and
women, our results indicated that the MRS, blood
pressure, blood glucose and triglycerides, were more
strongly associated with cancer mortality than with cancer
incidence. A possible explanation could be that metabolic
factors are involved both in tumour progression and its ini-
tiation,31 causing higher HRs for cancer mortality.
Obesity is often regarded as an underlying factor for
metabolic syndrome32 but it was not the primary factor
driving the association between MRS and cancer risk in our
study. Obesity assessed by BMI was only moderately related
to cancer risk in women and not related to risk in men,
which is in agreement with other studies.2,33 The strongest
individual risk factors for total incident cancer were in men
high levels of blood pressure and triglycerides, and in
women high blood glucose levels. Individual cancers that
have been strongly related to BMI, such as cancer of the
renal cells, oesophagus, endometrium and colorectum,1,2
were among the cancers that were most strongly related to
MRS in this study. Our previous analyses of these cancers
suggested that high BMI together with various other factors
in the MRS were the strongest individual risk factors.3,5,6,30
Liver cancer was in our previous study most strongly related
to blood glucose,14 and consequently liver cancer in men
Figure 2. Hazard ratio (HR) and 95% confidence interval of incident cancer at separate sites in men (A), women (B) and men and women combined (C)
by the metabolic risk score (MRS, mean¼0, SD¼ 1). HRs were derived from Cox regression models with attained age as timescale, strata for cohort,
birth year and sex and adjustment for baseline age and smoking status. HRs were corrected for a regression dilution ratio of 0.69 for metabolic risk
score by exp(log(HR)/0.69). ICD-7 180.0 and 180.9 denoting renal cell cancer, and ICD-7172 denoting endometrial cancer, include a fraction of tumours
that morphologically differ from the clinical classification of these cancers. HRs for cancer of the stomach, colon and pancreas differed significantly
between men and women, so these cancers are not included in (C). Phet refers to P-value for heterogeneity between cohorts which was tested by like-
lihood ratio tests in which a model with the continuous metabolic risk score was compared with a model additionally including a product term of
metabolic risk score and cohort.
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relative to other cancers was more strongly related to MRS
(1st rank) than it has been related to BMI. Although some
chance findings might have occurred given the many tests in
this study, overall our observations show that a combination
of high levels of metabolic risk factors increases the risk for
cancer, and the factor(s) driving the association varies be-
tween different cancer forms.
Our study has several strengths. It is very large and we
were able to follow participants for a long period of time.
Further, we were able to correct for measurement error and
long-term variations in metabolic factors by use of repeated
measurement data. Moreover, the capture rate of cancer
cases in Norway and Sweden was nearly 100% using of na-
tional cancer registers,34,35 and the cancer register in Austria
also indicates good coverage with approximately 95% of
cancer deaths covered by the cancer register.36
There are also some weaknesses in our study. We lacked
data on body composition and detailed blood lipid data,
for which BMI and total cholesterol served as surrogates.
Waist circumference is related to all-cause mortality inde-
pendently of BMI and is more strongly associated with
cancer risk than BMI.33 Although BMI is commonly used
in large epidemiological studies, it will not fully capture an
association when abdominal obesity rather than general
obesity and body size is the causal link to cancer. Also,
whereas serum high-density lipoproteins are commonly
included as lipid risk factors for cardiovascular disease,7
we had to use total cholesterol instead which is less spe-
cific. We also lacked data on socioeconomic factors,
diet, physical activity, hormonal and reproductive
factors in women and detailed data on tobacco smoking,
which might have confounded some of our observed
associations.
In conclusion, this study showed that an MRS of five
metabolic factors was positively associated with risk of
overall cancer incidence and mortality as well as incidence
from several separate cancers. The strongest associations
were found for renal cell and liver cancer in men and endo-
metrial and pancreatic cancer in women. Strong associ-
ations were found for cancers typically related to high BMI
and obesity, but factors other than BMI were in this study,
and in some previous Me-Can studies of single cancers,
stronger drivers of the MRS-cancer association.
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